MELBOURNE, Australia, May 16, 2014 (GLOBE NEWSWIRE) -- Propanc Health Group Corporation (OTCQB:PPCH) (“Propanc Health Group,” “Propanc” or “the Company”), a developmental stage a healthcare company focused on new cancer treatments for patients with solid tumors, today announced its key strategic objectives for the development of its lead product, PRP. This Company is now refocusing the preferred route of administration to intravenous (I.V.) injection. They are now targeting 2015 to prepare for and initiate human trials in patients with advanced colorectal and/or pancreatic cancers.
Help employers find you! Check out all the jobs and post your resume.
